Is ACRS or ADCT more undervalued in 2026?

CirclFi compares Aclaris Therapeutics, Inc. (ACRS) and ADC Therapeutics SA (ADCT) using 13 institutional-grade valuation models. ACRS has a Quality of Company score of 7.1/10 while ADCT scores 6.5/10.

Which is a better buy — ACRS or ADCT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ACRS and ADCT valuations compare?

ACRS at $4.57 and ADCT at $3.45 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ACRS vs ADCT Valuation Comparison 2026 — Intrinsic Value Analysis

ACRS

Biotechnology

Aclaris Therapeutics, Inc.

Quality

7.1

out of 10

Value Trap

LOW

Price

$4.57

Last close

Models

11/13

Active

ADCT

Biotechnology

ADC Therapeutics SA

Quality

6.5

out of 10

Value Trap

SAFE

Price

$3.45

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	ACRS Fair Value	ACRS Upside	ADCT Fair Value	ADCT Upside
Bayesian DCF	Intrinsic	$1.33	-70.8%	$1.33	-61.4%
Earnings Power Value	Intrinsic	$0.29	-93.5%	$3.34	-12.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ACRS vs ADCT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ACRS vs ADCT — Which Stock Is More Undervalued?

ACRS scores higher with a 7.1/10 quality rating vs ADCT's 6.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aclaris Therapeutics, Inc. (ACRS) and ADC Therapeutics SA (ADCT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ACRS currently trades at $4.57 with a QOC of 7.1/10, while ADCT trades at $3.45 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).